NCT04906993Active, not recruitingPhase 3
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
Source: ClinicalTrials.gov · Last updated 9 Sept 2025
Brief summary (registry, in English)
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 443 (actual)
- First submitted
- 26 May 2021
- Start date
- 23 Jul 2021
- Primary completion date
- 10 Jun 2025
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Diseases
- Cervical cancer
- NCT number
- NCT04906993
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 443
- From 23 Jul 2021 to the primary completion date, 10 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has any malignancy \<5 years prior to study entry.
- Received live vaccinations 4 weeks before randomization or during the study period
Other illness
- Known to have autoimmune disease
Other
- Known to have brain or meningeal metastasis
Who the study is looking for
- Female aged 18-75 years (including 18 and 75 years, calculated based on the signing date of the informed consent)
- Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy
- No prior systemic anti-cancer therapy for recurrent/metastatic disease
- According to RECIST v1.1 criteria, the patient must have at least one measurable lesion
- Able to normally swallow drug tablets
- The organ function level is good
- Willing to participate and able to comply with research programme requirements
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.